{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:37:59Z","timestamp":1792507079739,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of War","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clgc.2026.102679","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:15:29Z","timestamp":1789427729000},"page":"102679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Risk-Adapted Framework for Adjuvant Pembrolizumab Plus Belzutifan in Resected Clear Cell Renal Cell Carcinoma"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1736-5650","authenticated-orcid":false,"given":"Arighno","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1225-3959","authenticated-orcid":false,"given":"Brittney H.","family":"Cotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-8308","authenticated-orcid":false,"given":"Pavlos","family":"Msaouel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1638-1445","authenticated-orcid":false,"given":"Surena F.","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4079-9051","authenticated-orcid":false,"given":"Daniel D.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.clgc.2026.102679_bib0001","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clgc.2026.102679_bib0002","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa2518245","article-title":"Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma","volume":"395","author":"Choueiri","year":"2026","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.clgc.2026.102679_bib0003","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.3390\/cancers14163923","article-title":"A Causal Framework for Making Individualized Treatment Decisions in Oncology","volume":"14","author":"Msaouel","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7223","key":"10.1016\/j.clgc.2026.102679_bib0004","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","article-title":"Calculating the number needed to treat for trials where the outcome is time to an event","volume":"319","author":"Altman","year":"1999","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.clgc.2026.102679_bib0005","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clgc.2026.102679_bib0006","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.clgc.2026.102679_bib0007","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression Models and Life-Tables","volume":"34","author":"Cox","year":"1972","journal-title":"Journal of the Royal Statistical Society: Series B (Methodological)"},{"issue":"2","key":"10.1016\/j.clgc.2026.102679_bib0008","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal","volume":"38","author":"Phillippo","year":"2018","journal-title":"Med Decis Making"},{"issue":"1","key":"10.1016\/j.clgc.2026.102679_bib0009","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.eururo.2021.02.025","article-title":"Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma","volume":"80","author":"Correa","year":"2021","journal-title":"Eur Urol"},{"issue":"23","key":"10.1016\/j.clgc.2026.102679_bib0010","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.19.00107","article-title":"Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation","volume":"37","author":"Correa","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102679_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.11.016","article-title":"Belzutifan for renal cell carcinoma: Balancing regulatory approval with societal and patient impact","volume":"6","author":"Chahoud","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.clgc.2026.102679_bib0012","first-page":"1","article-title":"Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers","volume":"42","author":"Apolo","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"11","key":"10.1016\/j.clgc.2026.102679_bib0013","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.3390\/cancers13112741","article-title":"Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes","volume":"13","author":"Msaouel","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clgc.2026.102679_bib0014","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1517\/17425255.2016.1120287","article-title":"New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors","volume":"12","author":"Ciccarese","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102679_bib0015","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1017\/rsm.2025.10059","article-title":"The hazards of using hazard ratios from proportional hazard models in indirect treatment comparisons","volume":"17","author":"Jiang","year":"2026","journal-title":"Res Synth Methods"},{"issue":"3","key":"10.1016\/j.clgc.2026.102679_bib0016","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.urolonc.2024.10.022","article-title":"Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting","volume":"43","author":"Berg","year":"2025","journal-title":"Urol Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2026.102679_bib0017","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.urolonc.2025.07.020","article-title":"Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank","volume":"43","author":"Shapiro","year":"2025","journal-title":"Urol Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:57:08Z","timestamp":1791345428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":17,"alternative-id":["S1558767326001795"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102679","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Risk-Adapted Framework for Adjuvant Pembrolizumab Plus Belzutifan in Resected Clear Cell Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102679"}}